ALSO NOTED: TriMed raises $5M; Peregrine touts data; Celltrion announces manufacturing deal; Organon to meet with FDA; and much

> Omaha, Neb.-based TriMed Research has raised $5 million in its first round. Release

> Peregrine Pharmaceuticals is touting new clinical data supporting the broad anti-viral properties of Tarvacin. Release

> Celltrion, a joint venture of VaxGen, has inked a deal to manufacture biologics under development by Bristol-Myers Squibb. Release

> Organon says it will meet with FDA officials to address issues the agency has raised for its implantable contraceptive Implanon. Story

> Genelabs has received an orphan drug designation for its experimental lupus drug Prestara. Release

> Canada's Generex has started a research collaboration on an allergy therapy. Release

> Pfizer has begun work on a $90 million plant expansion in Ireland. Release

> Elite Pharmaceuticals and IntelliPharmaCeutics will jointly develop a controlled release product. Release

> Spain's Zeltia has launched a 100M euro share issue. Story

And finally...A doctor's troubled past took years to catch up with him in Australia. Article

Suggested Articles

Rachel Humphrey, M.D., who joined CytomX as chief medical officer after heading immuno-oncology at AstraZeneca and Eli Lilly, has made her exit.

Scientists have discovered a scorpion toxin could inspire treatments to block the inflammation that triggers chronic pain.

The phase 2 success keeps Hal Barron’s group on track to file for approval in multiple myeloma by the end of the year.